secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001104659-25-070554
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros prices $22M offering, discloses advanced partnership talks, narsoplimab PDUFA now Dec 2025
--------------------------------------------------------------------------------

- Sold 5,365,853 shares at $4.10 each to Polar Asset Management; net proceeds ~$20.3M; expected close July 28.
- Narsoplimab BLA PDUFA date extended from Sep 25, 2025 to Dec 26, 2025; labeling discussions planned by Oct 2025.
- Advanced partnership discussion: potential multi-billion transaction value excl. royalties; upfront would repay $67.1M term loan and $17.1M notes.
- Cash and equivalents $26.0M as of July 18; 61.8M shares outstanding.
- PDE7 inhibitor program: preclinical studies for cocaine use disorder completed; FDA requests more preclinical info.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/0001104659-25-070554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000110465925070554/tm2516030d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-070554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer